Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania.…
Savara (SVRA) Stock Looks Stretched As Its 338% Five Year Run Continues
Savara (NASDAQ: SVRA) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 70 employees.
The shares were at 4.260 USD on 20 November 2026, up 7.0% over 52 weeks. Its 52-week range is 3.860 USD to 7.005 USD: the price is 39.2% below the high and 10.4% above the low.
Its market capitalisation is 939.86M USD.
Savara reports return on equity of -58.5% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 99.74M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 9 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 10.83 USD is 154.3% above the current price. The next earnings report is expected on 12 March 2027.